Novo Study Shows Monthly Hemophilia Drug Reduced Bleeding [BNN Bloomberg (Canada)]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: BNN Bloomberg
Both weekly and monthly dosing with the compound, Mim8, reduced bleeding compared with no prophylaxis and with trial participants' own previous experience with other drugs, the Danish drugmaker said on Monday. About 95% of patients who got monthly shots of Mim8 didn't need to be treated for bleeding, compared to none of those who didn't have prophylaxis, Novo said. Novo and competitors are racing to develop new medicines for hemophilia A, a genetic disorder in which blood doesn't clot as it should. Preventing at least 80% of patients from needing to be treated for bleeding is a key determiner of whether Mim8 will be able to challenge rivals such as Roche Holding AG's Hemlibra, Jefferies analysts wrote before the results were released. Novo said it aims to submit Mim8 for its first regulatory approval toward the end of this year. ©2024 Bloomberg L.P. Top Picks
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer's disease [Yahoo! Finance]Yahoo! Finance
- New England Journal of Medicine Publishes Landmark Phase III Results for Genentech’s Itovebi, Showing More Than Doubling of Progression-Free Survival in Certain Type of HR-Positive Advanced Breast CancerBusiness Wire
- Neuvivo Expands Board of Directors in Preparation of Upcoming NDA Review with the Appointment of Robert Baffi, PhD, MBA [Yahoo! Finance]Yahoo! Finance
- Chugai Pharmaceutical Co., Ltd. 2024 Q3 - Results - Earnings Call Presentation [Seeking Alpha]Seeking Alpha
- Chugai Pharmaceutical Co., Ltd. (CHGCF) Q3 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha